Q3-osavuosiraportti
83 päivää sitten‧57 min
Tarjoustasot
First North Sweden
Määrä
Osto
78
Myynti
Määrä
7 116
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 482 | - | - | ||
| 1 043 | - | - | ||
| 75 | - | - | ||
| 885 | - | - | ||
| 900 | - | - |
Ylin
11,22VWAP
Alin
11,06VaihtoMäärä
0,5 43 704
VWAP
Ylin
11,22Alin
11,06VaihtoMäärä
0,5 43 704
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 49 910 | 49 910 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 49 910 | 49 910 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 8.10. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 25.6. | |
| Merkintäoikeusanti | 10.4. | |
| 2025 Q2-osavuosiraportti | 9.4. | |
| 2025 Q1-osavuosiraportti | 29.1. | |
| 2024 Yhtiökokous | 5.12.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
11.9.·Key findings from Diamyd's analysis Diamyd® delays the decline in the body's own insulin production in patients with type 1 diabetes who have the genetic marker HLA DR3-DQ2. The effect is particularly clear in patients who have received at least three injections of the drug. Patients maintained C-peptide levels above critical thresholds (0.2 and 0.5 nmol/L) for longer compared to placebo. The results strengthen previous findings from the DIAGNODE-2 and DIAGNODE-B studies, and provide support for the ongoing phase 3 study DIAGNODE-3. Diamyd® is an antigen-specific immunotherapy that targets autoimmune diabetes — that is, when the body's immune system attacks the insulin-producing cells. Preserved insulin production is linked to better blood sugar control and fewer complications.
5.9.·How much is it estimated that it will rise? on an ice? If you dare to throw a little more 😇
5.9.·Ok, say 20-25 thanks to FOMO before March-April and if the reading is positive in March/April the price could very well go up to 40-50 because the company has been valued in those areas in previous years. But based on its acquisition potential and future blockbuster, the share price will be breathtakingly much higher but there are a lot of "ifs and buts" for all the pieces to fall into place
20.8.·A good post written by the signature Alkemisten: With just over 6 months left until the reading in March 2026, it feels like we can really just sit back and wait for both the increasing FOMO and the results of the phase III study Diagnode-3. But a lot will happen before March and with each month the interest from researchers, investors and the large pharmaceutical companies that closely follow Diamyd Medical's development increases. We are facing the biggest paradigm shift in diabetes medicine in over 100 years. Not only have we developed a medicine that reprograms the immune system so that the autoimmune disease does not attack the insulin-producing beta cells in the pancreas, but we have also found which target group responds effectively to the treatment. Imagine that we are about to create a precision medicine for a disease that affects about 500,000 people worldwide annually and which is predicted to increase enormously in the coming decade. It smells like a Nobel Prize within a few years. Ahead of the phase III reading, the investors are of course very nervous as many have invested large sums in the company. However, I am personally confident in my investment and look forward to the results with confidence. Why this calm before such a crucial milestone? I look back and see that in previous meta-analysis, based on 3 previous studies, we already have a clinically relevant treatment effect and statistical significance. What we are doing in Diagnode-3 is repeating the results on a carefully balanced group of patients who we KNOW respond positively to Diamyd. In addition, we already have 6-month data from Diagnode-3 where an independent safety committee (DSMB) assessed that the study has the potential to achieve primary efficacy endpoints. We are waiting for some big news that will probably be the start of a relatively rapid increase in price until the reading. We of course have the GMP certification of the manufacturing facility. Something we have been waiting for for many years but which will be completed at the end of the year or the beginning of the next. Another global news that is in the works is that LADA will be recognized as type 1 diabetes and will no longer be considered another form of autoimmune diabetes. This will of course multiply the value of Diamyd Medical. Furthermore, there will be nice and important updates in the future regarding insulin-specific immunotherapy where we can target individuals with a DR4-DQ8 profile. If we add this target group to the target group for Diagnode -3 (who has the HLA DR3-DQ2 profile), we can conclude that we cover 90% of individuals who have type 1 diabetes. Why are there no acquisitions and large funds if everything looks so good? The answer here in this forum must be speculative. The fact that large funds are not present, or rather, are waiting until the reading in March 2026, unfortunately has to do with previous history where an earlier phase III study (2011) failed because it was not known, as we now know, that different HLA profiles respond differently to diamyd. Large funds had invested heavily at the time and many small savers lost a lot of money. I therefore believe that due to previous history, some large fund managers are waiting for the reading. But it is my conviction that Diamyd Medical, after reading in March 2026, will be the next big Swedish public stock. Why no buyout? The company is not driven solely by money. The vision is clear and for AEM there is only one goal, to be there all the way out and to see its "foster child" come to market and know that there is now a cure for the disease it has spent most of its life fighting. There have certainly been a number of offers from a few BPs but we are now in a position where we can set the rules of the game. Why sell ourselves cheap now when we can set our own price tag in the near future (which will be incredibly expensive). Partners will of course help us move forward in anticipation of a possible buyout after launch and this will of course be a trigger that few. It is my belief that we will have one or more partners on the track before March 2026. The above text is not a buy or sell recommendation but represents only my own thoughts and views on the company and the immediate future. But I am lyrical and state that we are sitting on a huge golden egg.- 7.8.·AEM links to this page on his LinkedIn profile: https://aktieraketer.substack.com/p/diamyd-medical?triedRedirect=true
- 31.7. · Muokattu·New video from the USA, Shared by Anders Essen-Möller. https://www.youtube.com/watch?v=07oC39XW_ks&ab_channel=Type-1DiabeticWarriors
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
83 päivää sitten‧57 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11.9.·Key findings from Diamyd's analysis Diamyd® delays the decline in the body's own insulin production in patients with type 1 diabetes who have the genetic marker HLA DR3-DQ2. The effect is particularly clear in patients who have received at least three injections of the drug. Patients maintained C-peptide levels above critical thresholds (0.2 and 0.5 nmol/L) for longer compared to placebo. The results strengthen previous findings from the DIAGNODE-2 and DIAGNODE-B studies, and provide support for the ongoing phase 3 study DIAGNODE-3. Diamyd® is an antigen-specific immunotherapy that targets autoimmune diabetes — that is, when the body's immune system attacks the insulin-producing cells. Preserved insulin production is linked to better blood sugar control and fewer complications.
- 5.9.·How much is it estimated that it will rise? on an ice? If you dare to throw a little more 😇5.9.·Ok, say 20-25 thanks to FOMO before March-April and if the reading is positive in March/April the price could very well go up to 40-50 because the company has been valued in those areas in previous years. But based on its acquisition potential and future blockbuster, the share price will be breathtakingly much higher but there are a lot of "ifs and buts" for all the pieces to fall into place
- 20.8.·A good post written by the signature Alkemisten: With just over 6 months left until the reading in March 2026, it feels like we can really just sit back and wait for both the increasing FOMO and the results of the phase III study Diagnode-3. But a lot will happen before March and with each month the interest from researchers, investors and the large pharmaceutical companies that closely follow Diamyd Medical's development increases. We are facing the biggest paradigm shift in diabetes medicine in over 100 years. Not only have we developed a medicine that reprograms the immune system so that the autoimmune disease does not attack the insulin-producing beta cells in the pancreas, but we have also found which target group responds effectively to the treatment. Imagine that we are about to create a precision medicine for a disease that affects about 500,000 people worldwide annually and which is predicted to increase enormously in the coming decade. It smells like a Nobel Prize within a few years. Ahead of the phase III reading, the investors are of course very nervous as many have invested large sums in the company. However, I am personally confident in my investment and look forward to the results with confidence. Why this calm before such a crucial milestone? I look back and see that in previous meta-analysis, based on 3 previous studies, we already have a clinically relevant treatment effect and statistical significance. What we are doing in Diagnode-3 is repeating the results on a carefully balanced group of patients who we KNOW respond positively to Diamyd. In addition, we already have 6-month data from Diagnode-3 where an independent safety committee (DSMB) assessed that the study has the potential to achieve primary efficacy endpoints. We are waiting for some big news that will probably be the start of a relatively rapid increase in price until the reading. We of course have the GMP certification of the manufacturing facility. Something we have been waiting for for many years but which will be completed at the end of the year or the beginning of the next. Another global news that is in the works is that LADA will be recognized as type 1 diabetes and will no longer be considered another form of autoimmune diabetes. This will of course multiply the value of Diamyd Medical. Furthermore, there will be nice and important updates in the future regarding insulin-specific immunotherapy where we can target individuals with a DR4-DQ8 profile. If we add this target group to the target group for Diagnode -3 (who has the HLA DR3-DQ2 profile), we can conclude that we cover 90% of individuals who have type 1 diabetes. Why are there no acquisitions and large funds if everything looks so good? The answer here in this forum must be speculative. The fact that large funds are not present, or rather, are waiting until the reading in March 2026, unfortunately has to do with previous history where an earlier phase III study (2011) failed because it was not known, as we now know, that different HLA profiles respond differently to diamyd. Large funds had invested heavily at the time and many small savers lost a lot of money. I therefore believe that due to previous history, some large fund managers are waiting for the reading. But it is my conviction that Diamyd Medical, after reading in March 2026, will be the next big Swedish public stock. Why no buyout? The company is not driven solely by money. The vision is clear and for AEM there is only one goal, to be there all the way out and to see its "foster child" come to market and know that there is now a cure for the disease it has spent most of its life fighting. There have certainly been a number of offers from a few BPs but we are now in a position where we can set the rules of the game. Why sell ourselves cheap now when we can set our own price tag in the near future (which will be incredibly expensive). Partners will of course help us move forward in anticipation of a possible buyout after launch and this will of course be a trigger that few. It is my belief that we will have one or more partners on the track before March 2026. The above text is not a buy or sell recommendation but represents only my own thoughts and views on the company and the immediate future. But I am lyrical and state that we are sitting on a huge golden egg.
- 7.8.·AEM links to this page on his LinkedIn profile: https://aktieraketer.substack.com/p/diamyd-medical?triedRedirect=true
- 31.7. · Muokattu·New video from the USA, Shared by Anders Essen-Möller. https://www.youtube.com/watch?v=07oC39XW_ks&ab_channel=Type-1DiabeticWarriors
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
78
Myynti
Määrä
7 116
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 482 | - | - | ||
| 1 043 | - | - | ||
| 75 | - | - | ||
| 885 | - | - | ||
| 900 | - | - |
Ylin
11,22VWAP
Alin
11,06VaihtoMäärä
0,5 43 704
VWAP
Ylin
11,22Alin
11,06VaihtoMäärä
0,5 43 704
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 49 910 | 49 910 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 49 910 | 49 910 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 8.10. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 25.6. | |
| Merkintäoikeusanti | 10.4. | |
| 2025 Q2-osavuosiraportti | 9.4. | |
| 2025 Q1-osavuosiraportti | 29.1. | |
| 2024 Yhtiökokous | 5.12.2024 |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
83 päivää sitten‧57 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 8.10. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 25.6. | |
| Merkintäoikeusanti | 10.4. | |
| 2025 Q2-osavuosiraportti | 9.4. | |
| 2025 Q1-osavuosiraportti | 29.1. | |
| 2024 Yhtiökokous | 5.12.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11.9.·Key findings from Diamyd's analysis Diamyd® delays the decline in the body's own insulin production in patients with type 1 diabetes who have the genetic marker HLA DR3-DQ2. The effect is particularly clear in patients who have received at least three injections of the drug. Patients maintained C-peptide levels above critical thresholds (0.2 and 0.5 nmol/L) for longer compared to placebo. The results strengthen previous findings from the DIAGNODE-2 and DIAGNODE-B studies, and provide support for the ongoing phase 3 study DIAGNODE-3. Diamyd® is an antigen-specific immunotherapy that targets autoimmune diabetes — that is, when the body's immune system attacks the insulin-producing cells. Preserved insulin production is linked to better blood sugar control and fewer complications.
- 5.9.·How much is it estimated that it will rise? on an ice? If you dare to throw a little more 😇5.9.·Ok, say 20-25 thanks to FOMO before March-April and if the reading is positive in March/April the price could very well go up to 40-50 because the company has been valued in those areas in previous years. But based on its acquisition potential and future blockbuster, the share price will be breathtakingly much higher but there are a lot of "ifs and buts" for all the pieces to fall into place
- 20.8.·A good post written by the signature Alkemisten: With just over 6 months left until the reading in March 2026, it feels like we can really just sit back and wait for both the increasing FOMO and the results of the phase III study Diagnode-3. But a lot will happen before March and with each month the interest from researchers, investors and the large pharmaceutical companies that closely follow Diamyd Medical's development increases. We are facing the biggest paradigm shift in diabetes medicine in over 100 years. Not only have we developed a medicine that reprograms the immune system so that the autoimmune disease does not attack the insulin-producing beta cells in the pancreas, but we have also found which target group responds effectively to the treatment. Imagine that we are about to create a precision medicine for a disease that affects about 500,000 people worldwide annually and which is predicted to increase enormously in the coming decade. It smells like a Nobel Prize within a few years. Ahead of the phase III reading, the investors are of course very nervous as many have invested large sums in the company. However, I am personally confident in my investment and look forward to the results with confidence. Why this calm before such a crucial milestone? I look back and see that in previous meta-analysis, based on 3 previous studies, we already have a clinically relevant treatment effect and statistical significance. What we are doing in Diagnode-3 is repeating the results on a carefully balanced group of patients who we KNOW respond positively to Diamyd. In addition, we already have 6-month data from Diagnode-3 where an independent safety committee (DSMB) assessed that the study has the potential to achieve primary efficacy endpoints. We are waiting for some big news that will probably be the start of a relatively rapid increase in price until the reading. We of course have the GMP certification of the manufacturing facility. Something we have been waiting for for many years but which will be completed at the end of the year or the beginning of the next. Another global news that is in the works is that LADA will be recognized as type 1 diabetes and will no longer be considered another form of autoimmune diabetes. This will of course multiply the value of Diamyd Medical. Furthermore, there will be nice and important updates in the future regarding insulin-specific immunotherapy where we can target individuals with a DR4-DQ8 profile. If we add this target group to the target group for Diagnode -3 (who has the HLA DR3-DQ2 profile), we can conclude that we cover 90% of individuals who have type 1 diabetes. Why are there no acquisitions and large funds if everything looks so good? The answer here in this forum must be speculative. The fact that large funds are not present, or rather, are waiting until the reading in March 2026, unfortunately has to do with previous history where an earlier phase III study (2011) failed because it was not known, as we now know, that different HLA profiles respond differently to diamyd. Large funds had invested heavily at the time and many small savers lost a lot of money. I therefore believe that due to previous history, some large fund managers are waiting for the reading. But it is my conviction that Diamyd Medical, after reading in March 2026, will be the next big Swedish public stock. Why no buyout? The company is not driven solely by money. The vision is clear and for AEM there is only one goal, to be there all the way out and to see its "foster child" come to market and know that there is now a cure for the disease it has spent most of its life fighting. There have certainly been a number of offers from a few BPs but we are now in a position where we can set the rules of the game. Why sell ourselves cheap now when we can set our own price tag in the near future (which will be incredibly expensive). Partners will of course help us move forward in anticipation of a possible buyout after launch and this will of course be a trigger that few. It is my belief that we will have one or more partners on the track before March 2026. The above text is not a buy or sell recommendation but represents only my own thoughts and views on the company and the immediate future. But I am lyrical and state that we are sitting on a huge golden egg.
- 7.8.·AEM links to this page on his LinkedIn profile: https://aktieraketer.substack.com/p/diamyd-medical?triedRedirect=true
- 31.7. · Muokattu·New video from the USA, Shared by Anders Essen-Möller. https://www.youtube.com/watch?v=07oC39XW_ks&ab_channel=Type-1DiabeticWarriors
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
78
Myynti
Määrä
7 116
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 482 | - | - | ||
| 1 043 | - | - | ||
| 75 | - | - | ||
| 885 | - | - | ||
| 900 | - | - |
Ylin
11,22VWAP
Alin
11,06VaihtoMäärä
0,5 43 704
VWAP
Ylin
11,22Alin
11,06VaihtoMäärä
0,5 43 704
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 49 910 | 49 910 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 49 910 | 49 910 | 0 | 0 |